Revolution Medicines' pancreatic cancer therapy Rasonque moves closer to European approval after FDA clearance

Revolution Medicines' experimental drug Rasonque, aimed at treating pancreatic cancer, has received a recommendation for approval from European regulators.

The recommendation follows an earlier positive decision by the U.S. Food and Drug Administration, which had already granted the therapy a green light.

If the European approval is finalized, Rasonque would become one of the few new options for a disease with limited treatment choices, marking a notable milestone for the company and the oncology field.